Literature DB >> 10962534

Pregnancy after treatment of secondary acute promyelocytic leukemia following Hodgkin's disease: a case report.

I Elezović1, M Colović, D Tomin, D Bosković.   

Abstract

The authors report a case of therapy-related acute promyelocytic leukemia (t-APL), with typical cytogenetic translocation t(15;17), which appeared following chemotherapy (ABVD), and radiotherapy for Hodgkin's disease (IIB). After treatment with all-trans retinoic acid (Vesanoid(R) 45 mg/m2 daily) complete remission of t-APL was achieved. Then only one course of chemotherapy '3+7' (doxorubicin 45 mg/m2 1-3 d, cytosar 200 mg/m2 1-7d) was applied and the patient interrupted further treatment in July 1994. Four years later she had a normal pregnancy and delivered a healthy female infant in December 1998.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10962534     DOI: 10.1007/BF02780532

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  12 in total

1.  Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II.

Authors:  A De Renzo; L F Santoro; R Notaro; F Pane; M R Buonaiuto; L Luciano; B Rotoli
Journal:  Am J Hematol       Date:  1999-04       Impact factor: 10.047

2.  Acute promyelocytic leukaemia with t(15;17) following treatment of Hodgkin's disease--a report of 4 cases.

Authors:  S Gillis; O Sofer; O Zelig; E J Dann; H Lotan; D Ben Yehuda; R Isacson; E A Rachmilewitz; I Ben-Bassat; A Polliack
Journal:  Ann Oncol       Date:  1995-10       Impact factor: 32.976

3.  Acute promyelocytic leukaemia and Hodgkin's disease in the same patient.

Authors:  N G Flanagan; A Whitson; K B Patel; J C Ridway
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

4.  Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?

Authors:  P Y Dietrich; M Henry-Amar; J M Cosset; S Bodis; J Bosq; M Hayat
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

5.  Acute promyelocytic leukemia following ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy for Hodgkin's disease.

Authors:  S Amadori; G Papa; A P Anselmo; P Fidani; F Mandelli; C Biagini
Journal:  Cancer Treat Rep       Date:  1983-06

6.  All-trans retinoic acid for the treatment of acute promyelocytic leukemia in pregnancy.

Authors:  M H Incerpi; D A Miller; R Posen; J D Byrne
Journal:  Obstet Gynecol       Date:  1997-05       Impact factor: 7.661

7.  Effect of all-trans-retinoic acid alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukaemia.

Authors:  M D Colović; G M Janković; I Elezović; A Vidović; J S Bila; A Novak; D Babić
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.064

8.  The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.

Authors:  E Brusamolino; A P Anselmo; C Klersy; M Santoro; E Orlandi; G Pagnucco; F Lunghi; R Maurizi-Enrici; C D Baroni; M Lazzarino; F Mandelli; C Bernasconi
Journal:  Haematologica       Date:  1998-09       Impact factor: 9.941

9.  Successful treatment of acute promyelocytic leukaemia with all-trans-retinoic-acid during late pregnancy.

Authors:  M M Lipovsky; D H Biesma; G C Christiaens; E J Petersen
Journal:  Br J Haematol       Date:  1996-09       Impact factor: 6.998

Review 10.  Acute promyelocytic leukemia and pregnancy. A case report.

Authors:  M A Hoffman; P H Wiernik; G J Kleiner
Journal:  Cancer       Date:  1995-12-01       Impact factor: 6.860

View more
  1 in total

Review 1.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.